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Abstract
Background: The vaccinia virus (VV) F2L gene encodes a functional deoxyuridine triphosphatase
(dUTPase) that catalyzes the conversion of dUTP to dUMP and is thought to minimize the
incorporation of deoxyuridine residues into the viral genome. Previous studies with with a
complex, multigene deletion in this virus suggested that the gene was not required for viral
replication, but the impact of deleting this gene alone has not been determined in vitro or in vivo.
Although the crystal structure for this enzyme has been determined, its potential as a target for
antiviral therapy is unclear.
Results: The F2L gene was replaced with GFP in the WR strain of VV to assess its effect on viral
replication. The resulting virus replicated well in cell culture and its replication kinetics were almost
indistinguishable from those of the wt virus and attained similar titers. The virus also appeared to
be as pathogenic as the WR strain suggesting that it also replicated well in mice. Cells infected with
the dUTPase mutant would be predicted to affect pyrimidine deoxynucleotide pools and might be
expected to exhibit altered susceptibility to pyrimidine analogs. The antiviral activity of cidofovir
and four thymidine analogs were evaluated both in the mutant and the parent strain of this virus.
The dUTPase knockout remained fully susceptible to cidofovir and idoxuridine, but was
hypersensitive to the drug (N)-methanocarbathymidine, suggesting that pyrimidine metabolism was
altered in cells infected with the mutant virus. The absence of dUTPase should reduce cellular
dUMP pools and may result in a reduced conversion to dTMP by thymidylate synthetase or an
increased reliance on the salvage of thymidine by the viral thymidine kinase.
Conclusion:  We confirmed that F2L was not required for replication in cell culture and
determined that it does not play a significant role on virulence of the virus in intranasally infected
mice. The recombinant virus is hypersensitive to (N)-methanocarbathymidine and may reflect
metabolic differences in the mutant virus.
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Background
All free-living organisms have mechanisms to minimize
the incorporation of uracil in their genomes. These resi-
dues in DNA can arise either through misincorporation of
dUTP by DNA polymerase or the spontaneous deamina-
tion of cytosine and can result in A:T transition mutations
in one of the nascent strands [1]. Minimizing the incorpo-
ration of these bases and excising those that arise prevents
the accumulation of deleterious mutations. The enzymes
uracil DNA glycosylase (UNG) and deoxyuridine triphos-
phatase (dUTPase) arose very early in evolutionary terms
and act in concert to protect organisms from uracil resi-
dues [2,3]. Enzymes with dUTPase activity catalyze the
dephosphorylation of dUTP to minimize its incorpora-
tion into genomic DNA, while UNG family members
repair uracil residues from DNA by base excision repair.
These protective enzymes are also present in many viruses
including retroviruses, herpesviruses and orthopoxviruses
[4]. Proteins with UNG activity are either encoded by
these viruses, or recruited by viral proteins and are
thought to be important in viral replication [1]. Similarly,
dUTPase homologs are encoded by many lentiviruses, as
well as all herpesviruses and orthopoxviruses and are pre-
sumed to minimize potential damage by the incorpora-
tion of uracil residues [3]. Both herpes simplex virus
(HSV) and vaccinia virus (VV) encode homologs of dUT-
Pase and the viral enzymes hydrolyze dUTP to dUMP and
require divalent cations for their activity [5,6]. The dUT-
Pase encoded by the F2L gene of VV is a 16.5 kiloDalton
protein that forms homotrimers and enzymatic studies
determined that the Km for dUTP was 1 μM and that it was
competitively inhibited by 8-azido-ATP [7]. Recently, the
crystal structure of this trimeric enzyme was determined
and proved to be closely related to that of the human
homolog, although the central channel was somewhat
larger in the viral enzyme. These results suggested that the
development of specific inhibitors of this enzyme might
be possible [8].
If the dUTPase fulfills an essential role in viral replication
then inhibitors of this enzyme might have the potential to
be used in the treatment of orthopoxvirus infections. One
previous report described a recombinant virus with a large
deletion resulting in the elimination of 55 open reading
frames including F2L [9]. This recombinant was viable
suggesting that the dUTPase was not required for replica-
tion in cell culture, although it did not exclude the possi-
bility that it might be important for replication in vivo. In
HSV, deletion of the dUTPase homolog did not effect the
replication of the virus in vitro, however its virulence was
reduced by 1000-fold in mice following footpad inocula-
tion and reduced replication in the CNS was also observed
[10]. To assess the potential of the dUTPase as a target for
antiviral therapy, F2L was deleted in the WR strain of VV
and the replication of the mutant virus (VV Δ F2L-gfp) was
evaluated in cell culture and in intranasally infected mice.
The deletion of F2L had a minimal impact on viral repli-
cation in vitro and did not appear to significantly reduce
the virulence in vivo suggesting that it did not contribute
appreciably to disease, and that it was not a good target for
the development of antiviral therapies.
Results
A recombinant virus lacking only the dUTPase gene was
constructed by homologous recombination in the WR
strain of VV. In this virus, F2L was replaced with the gfp
gene driven by the synthetic E/L promoter. Fluorescent
recombinant plaques were plaque purified three times to
eliminate any contaminating wild type (wt) parental
virus. The insertion of the gfp resulted in the deletion of
most of the F2L open reading frame from amino acids
Genomic structure of the F2L region of VV Δ F2L-gfp Figure 1
Genomic structure of the F2L region of VV Δ F2L-gfp. The F2L gene in VV strain WR (shaded arrow in the top line) was 
replaced with the gfp gene driven by the synthetic E/L promoter (black arrow in the bottom line). The resulting virus was des-
ignated VV Δ F2L-gfp and contained a deletion in F2L corresponding to amino acids 11–129 of the open reading frame.
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11–129 (Fig. 1). The engineered mutation did not appear
to affect plaque size and confirmed that F2L was not
required for replication in cell culture (data not shown).
The replication kinetics of this virus were assessed in
human foreskin fibroblast (HFF) cells at an MOI of 0.001
PFU/cell. Results from this experiment suggested that the
F2L mutant (VVΔF2L-gfp) replicated well in these cells
and yielded titers that were reproducibly reduced com-
pared to those of the parent virus (Fig. 2). However, the
slight impairment in replication was so minor that it is
unlikely to be an important factor in cell culture. These
results suggested that the dUTPase is not required for the
replication of VV in cell culture and are consistent with the
previous report.
Although deletion of the dUTPase gene did not appear to
affect replication in cell culture, it is possible that it may
play a significant role in vivo as has been seen with the
dUTPase knockout virus in HSV. To test this hypothesis, 3
week old female, BALB/c mice were anesthetized with ket-
amine-xylazine and inoculated intranasally with 10-fold
dilutions of the viruses in a volume of 40 μl (20 μl per
nostril). Two isolates of wt VV WR, and VV Δ F2L-gfp were
evaluated in this experiment to assess the virulence char-
acteristic of these strains. Mice were observed daily for 21
days and were evaluated for clinical signs of infection and
mortality. Infection with 1.6 × 104 PFU or greater resulted
in 100% mortality, while some animals survived with 10-
fold less virus (Table 1). Thus, no significant differences
were observed in the virulence among the two isolates of
WR and the mutant virus. These results suggested that
dUTPase is not required for virulence in mice and its
removal does not appear to impact viral replication in ani-
mals.
Deletion of the dUTPase is predicted to effect pyrimidine
metabolism in infected cells and may alter the susceptibil-
ity of the mutant virus to some antiviral drugs. A set of
thymidine analogs was selected and a standard plaque
reduction assay was used to evaluate the susceptibility of
the dUTPase mutant and the parent virus. The mutant
remained fully sensitive to all of the drugs tested including
cidofovir (CDV), idoxuridine (IDU), and two thymidine
analogs reported to require phosphorylation by the VV
thymidine kinase (TK) [11]. The only significant differ-
ence observed in the mutant virus was the modest but
repeatable increase in the efficacy of N-methanocarbathy-
midine (N-MCT) (Table 2). This compound is a carbocy-
clic thymidine analog that inhibits the replication of VV
both in vitro and in vivo [12,13], and also appears to
require phosphorylation by the viral TK [12].
Discussion
Results presented here are consistent with a previous
report that showed that the dUTPase was not required for
Table 1: VV Δ F2L-gfp exhibits virulence characteristics that are 
similar to the parent virus.
Virus (PFU/mouse)a Mortality MDDb
Number Percent
VV-WR, UAB
1.6 × 104 10/10 100 6.8 ± 0.8
1.6 × 103 3/10 30 8.3 ± 0.6
1.6 × 102 0/10 0 ---
16 0/10 0 ---
1.6 0/10 0 ---
VV-WR, Turner
Stock 1.6 × 108 10/10 100 3.2 ± 0.4
1.6 × 107 10/10 100 3.9 ± 0.3
1.6 × 106 10/10 100 5.1 ± 0.3
1.6 × 105 10/10 100 6.2 ± 0.4
1.6 × 104 10/10 100 7.9 ± 1.0
VV Δ F2L-gfp
Stock 6 × 107 10/10 100 4.2 ± 0.4
6 × 106 10/10 100 4.7 ± 0.5
6 × 105 10/10 100 6.1 ± 0.6
6 × 104 10/10 100 7.1 ± 0.3
6 × 103 5/10 50 8.4 ± 0.5
a. Anesthetized mice were inoculated intranasally with 40 μl of virus 
(20 μl/nostril).
b. Mean day of death (MDD) is shown with the standard deviation.
Replication kinetics of VV Δ F2L-gfp in HFF cells Figure 2
Replication kinetics of VV Δ F2L-gfp in HFF cells. Triplicate 
wells of 6-well plates were infected with the WR strain of VV 
(square symbols) or VV Δ F2L-gfp (circular symbols). Virus 
from each well was harvested at 2, 8, 12, 24, 36, and 48 h 
post infection. All samples including inocula were titered in 
duplicate and average titers are shown with error bars rep-
resenting the standard deviations.
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replication in cell culture using a virus containing a mul-
tigene deletion [9]. They also suggest that the function of
this protein is of modest importance in the replication of
VV in vivo. These results contrast with those reported pre-
viously for the dUTPase negative mutants of HSV where
virulence was severely affected in mice [10]. It is unclear if
the observed differences in replication in mice reflect real
differences in the biology of these viruses, or are related to
differences in the animal models including route of infec-
tion. In HSV, direct intracranial inoculation resulted in a
10-fold reduction in virulence of the mutant, whereas
footpad inoculation increased the LD50 from approxi-
mately 103 PFU to more than 106 PFU of the mutant virus.
Thus, the observed virulence of the HSV mutant was
dependent on the route of administration and it is unclear
if reduced virulence would be observed following intrana-
sal inoculation.
We show here that there is little if any attenuation when
mice are intranasally infected with VV in which the dUT-
Pase has been deleted. Additional experiments are
required to resolve this issue and the rabbit model of VV
infection and might be a more sensitive indicator of
reduced virulence associated with the mutant virus [14]. It
is also possible that reduced virulence might be observed
if infection was initiated through inoculation at periph-
eral sites.
Differences in pyrimidine metabolism were predicted to
occur in the absence of the dUTPase so a set of selected
thymidine analogs were used as potential indicators of
metabolic differences. The efficacy of the CDV control
virus was unchanged in the mutant, as was the activity of
IDU and two thymidine analogs reported previously [11].
However, the mutation in VV ΔF2L-gfp appeared to confer
some hypersensitivity to the drug (N)-MCT. The mecha-
nism of action of this compound is incompletely under-
stood, although it appears to require phosphorylation by
the viral TK to the monophosphate (N-MCT-MP) [12].
This is significant since intracellular pools of dUMP and
dTMP are predicted to be reduced in the absence of the
viral dUTPase. Thus, the increased ratios of N-MCT-
MP:dTMP and N-MCT-MP:dUMP should reduce competi-
tion for subsequent anabolic reactions or as substrates for
the target enzyme, perhaps thymidylate synthetase (Fig.
3). It is unclear why this was not observed with IDU and
the other compounds, but it likely reflects the specific
mechanisms of the individual drugs.
Conclusion
Data presented here suggest that VV dUTPase is not
required for viral replication in cell culture. The deletion
of F2L also does not appear to impact the virulence of the
virus in mice following intranasal infection. These studies
suggest that dUTPase is not a particularly good target for
the development of antiviral therapies, although it
remains possible that other animal models may identify
an important function of this enzyme. The mutation does
not affect the efficacy of most antiviral drugs including
CDV although it appears to confer a modest hypersensi-
tivity to N-MCT and may reflect metabolic differences in
the mutant virus.
Model of dUTPase function in VV and a potential explanation  of (N)-MCT hypersensitivity Figure 3
Model of dUTPase function in VV and a potential explanation 
of (N)-MCT hypersensitivity. Deletion of dUTPase is pre-
dicted to reduce intracellular pools of its dUMP product, 
which is converted to dTMP by thymidylate synthetase. This 
is significant since dTMP is predicted to compete with the 
monophosphate metabolite of N-MCT (N-MCT-MP) for sub-
sequent anabolic reactions or as substrates for the target 
enzyme.
Table 2: Susceptibility of VV Δ F2L-gfp to selected thymidine analogs and cidofovir.
Compound Name VV Δ F2L-gfp (EC50, μM)a VV WR wt (EC50, μM)
IDU 2.5 ± 0.9 2.4 ± 0.6
N-MCT 6.2 ± 3.5 12 ± 1.6
PFT3 2.0 ± 0.6 2.4 ± 0.4
PFT4 2.3 ± 1.1 2.5 ± 0.1
CDV 11 ± 4.2 10 ± 0.3
a. Concentration required to reduce plaque formation by 50%. Values shown are the average of duplicate determinations with the standard 
deviations shown.Virology Journal 2008, 5:39 http://www.virologyj.com/content/5/1/39
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Methods
Cells, viruses, and drugs
Recombinant virus designated VV ΔF2L-gfp and the
parental wt VV strain WR (Turner) were received from Dr.
Pete Turner, University of Florida, Gainesville, FL. VV
strain WR (UAB) used in the animal studies was obtained
from the American Type Culture Collection (ATCC), Man-
assas, VA. Working stocks of both VV-WR isolates and VV
ΔF2L-gfp were propagated in Vero cells obtained from
ATCC. Human foreskin fibroblasts were prepared as pri-
mary cultures from freshly obtained newborn human
foreskins as soon as possible after circumcision. Culture
medium for both cell lines was minimum essential
medium (MEM) with Earle's salts containing 10% fetal
bovine serum and standard concentrations of L-
glutamine, penicillin and gentamicin.
The drugs tested included CDV, IDU, N-MCT, 5-(2-
amino-3-cyano-5-oxo-5,6,7,8-tetrahydro-4H-chromen-4-
yl)-1-(2-deoxypento-furanosyl)-pyrimidine-2,4(1H,3H)-
dione (PFT3), and 1-(2-deoxypentofuranosyl)-5- [(3-
methyl-5-oxo-1-phenyl-4,5-dihydro-4H-pyrazol-4-yli-
dene)pyrimidine-2,4(1H,3H)-dione (PFT4). Compounds
designated PFT3 and PFT4 were synthesized by Paul Tor-
rence (Northern Arizona University) and were described
previously [11]; N-MCT was described previously [15];
CDV was a gift of Mick Hitchcock at Gilead sciences and
IDU was purchased from Sigma Aldrich (St. Louis, MO).
Construction of VV ΔF2L-gfp
A recombinant was constructed from VV strain WR with
most of F2L replaced with the gfp gene driven by the syn-
thetic E/L promoter by methods similar to those described
previously [16]. Primers IDT 715 (5'-ATGCTGCTTGGGT-
TAATATGCCG-3') against the F3L gene upstream from
F2L and IDT 716 (GCGAAGCTTAACTGGTGAGTTAATAT-
TCATGTTGAAC, HindIII site underlined) against the com-
plement of F2L residues 3–31 were used to PCR amplify a
487-bp fragment upstream from F2L. A 531-bp PCR prod-
uct consisting of the downstream flank from F2L was
made using primers IDT 717 (GCGCTCGAGAGGGTTT-
GGATCAACAGGAC,  XhoI site underlined) against F2L
residues 417–436 and IDT 718 (CATACATCGTCTAC-
CCAATTCGG) against F1L. HindIII-digested, dephospho-
rylated IDT 715+716 PCR product and XhoI-digested,
dephosphorylated IDT 717+718 PCR product were
ligated to a HindIII-XhoI restriction fragment consisting of
the PE/L promoter linked to the gfp gene. The ligation mix
was PCR amplified with primers IDT 715 and IDT 718 to
generate a 1.8-kb product of gfp flanked by portions of
F3L and F1L. CV-1 cells were infected with wt VV-WR,
transfected with the F3L-gfp-F1L DNA, and plaques
expressing gfp were isolated by fluorescence. The resulting
virus was designated VV ΔF2L-gfp and contained a dele-
tion in F2L corresponding to amino acids 11–129 of the
open reading frame. The genomic structure and purity of
this virus was confirmed by PCR using primers IDT 715 +
718. No fragment of 1.4 kb corresponding to wt F2L plus
flanks was detected, but a 1.8 kb fragment of F3L-gfp-F1L
was present.
Growth curves
To determine the in vitro replication of the viruses, HFF
cells were incubated in 6 well plates for 24 h prior to infec-
tion at 37°C with 5% CO2 and 90% humidity. Triplicate
wells were infected with wt VV-WR or VV Δ F2L-gfp at an
MOI of 0.001. Infected plates were frozen at -80°C at 2, 8,
12, 24, 36 and 48 h post infection. Duplicate titrations of
each of the triplicate wells were conducted in HFF cells in
6 well plates. Plaques were enumerated and titers were
determined for each time point and virus.
Determination of antiviral activity
Plaque reduction assays were performed using HFF cells
added to six well plates and incubated 48 h prior to infec-
tion. On the day of assay, drug at two times the final
desired concentration was diluted serially 1:5 in 2X MEM
with 10% FBS to provide six concentrations. Aspiration of
culture medium from triplicate wells for each drug con-
centration was followed by addition of 0.2 ml/well of
diluted virus which would give 20–30 plaques per well in
MEM containing 10% FBS or 0.2 ml medium for drug tox-
icity wells. The plates were incubated for one h with shak-
ing every 15 minutes. An equal amount of 1% agarose was
added to an equal volume of each drug dilution and this
mixture was added to each well in 2 ml volumes and the
plates incubated for three days. The cells were stained with
a 0.02% solution of neutral red (Sigma, St. Louis, MO) in
PBS and incubated for 5–6 h. The stain was aspirated, and
plaques counted using a stereomicroscope at 10× magni-
fication and 50% effective concentration (EC50) values
were calculated by standard methods.
Virulence
Three week old female, BALB/c mice were anesthetized
with ketamine-xylazine and inoculated intranasally with
10-fold dilutions of the viruses in a volume of 40 μl (20
μl per nostril). Two isolates of WR, and VV Δ F2L-gfp were
evaluated in this experiment to assess the virulence char-
acteristic of these strains. Mice were observed daily for 21
days and were evaluated for clinical signs of infection and
mortality.
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(dUDP), deoxyuridine monophosphate (dUMP), green
fluorescent protein (GFP), deoxythymidine monophos-
phated (TMP), uracil DNA glycosylase (UNG), human
foreskin fibroblast (HFF), lethal dose 50% (LD50), effec-
tive concentration (EC50), American type culture collec-
tion (ATCC), 5-(2-amino-3-cyano-5-oxo-5,6,7,8-
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syl)-pyrimidine-2,4(1H,3H)-dione (PFT3), 1-(2-deox-
ypentofuranosyl)-5-[(3-methyl-5-oxo-1-phenyl-4,5-
dihydro-4H-pyrazol-4-ylidene)pyrimidine-2,4(1H,3H)-
dione (PFT4), minimum essential medium (MEM), cen-
tral nervous system (CNS).
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
MNP contributed to the design of experiments, analysis of
the data and the drafted the manuscript. ERK contributed
to the conception of the studies and the critical review of
the manuscript. DCQ contributed to the design of the
experiments and analysis of the data. KAK contributed to
the acquisition and interpretation of data. RWM contrib-
uted to the conception of the studies and the critical
review of the manuscript. PCT contributed to the design of
experiments, the acquisition and analysis of data and the
critical review of the manuscript.
Acknowledgements
These studies were supported by Public Health Service contracts NO1-AI-
30049 and NO1-AI-15439, grant 2R56AI015722-25 to RWM and grant 1-
U54-AI-057157 from the NIAID, NIH.
References
1. Priet S, Sire J, Querat G: Uracils as a cellular weapon against
viruses and mechanisms of viral escape.  Curr HIV Res 2006,
4(1):31-42.
2. Krokan HE, Drablos F, Slupphaug G: Uracil in DNA--occurrence,
consequences and repair.  Oncogene 2002, 21(58):8935-8948.
3. McClure MA: Evolution of the DUT gene: horizontal transfer
between host and pathogen in all three domains of life.  Curr
Protein Pept Sci 2001, 2(4):313-324.
4. Chen R, Wang H, Mansky LM: Roles of uracil-DNA glycosylase
and dUTPase in virus replication.  J Gen Virol 2002, 83(Pt
10):2339-2345.
5. Broyles SS: Vaccinia virus encodes a functional dUTPase.  Virol-
ogy 1993, 195(2):863-865.
6. Caradonna SJ, Adamkiewicz DM: Purification and properties of
the deoxyuridine triphosphate nucleotidohydrolase enzyme
derived from HeLa S3 cells. Comparison to a distinct dUTP
nucleotidohydrolase induced in herpes simplex virus-
infected HeLa S3 cells.  J Biol Chem 1984, 259(9):5459-5464.
7. Roseman NA, Evans RK, Mayer EL, Rossi MA, Slabaugh MB: Purifica-
tion and characterization of the vaccinia virus deoxyuridine
triphosphatase expressed in Escherichia coli.  J Biol Chem 1996,
271(38):23506-23511.
8. Samal A, Schormann N, Cook WJ, DeLucas LJ, Chattopadhyay D:
Structures of vaccinia virus dUTPase and its nucleotide com-
plexes.  Acta Crystallogr D Biol Crystallogr 2007, 63(Pt 5):571-580.
9. Perkus ME, Goebel SJ, Davis SW, Johnson GP, Norton EK, Paoletti E:
Deletion of 55 open reading frames from the termini of vac-
cinia virus.  Virology 1991, 180(1):406-410.
10. Pyles RB, Sawtell NM, Thompson RL: Herpes simplex virus type
1 dUTPase mutants are attenuated for neurovirulence, neu-
roinvasiveness, and reactivation from latency.  J Virol 1992,
66(11):6706-6713.
11. Prichard MN, Keith KA, Johnson MP, Harden EA, McBrayer A, Luo M,
Qiu S, Chattopadhyay D, Fan X, Torrence PF, Kern ER: Selective
phosphorylation of antiviral drugs by vaccinia virus thymi-
dine kinase.  Antimicrob Agents Chemother 2007, 51(5):1795-1803.
12. Prichard MN, Keith KA, Quenelle DC, Kern ER: Activity and
mechanism of action of N-methanocarbathymidine against
herpesvirus and orthopoxvirus infections.  Antimicrob Agents
Chemother 2006, 50(4):1336-1341.
13. Smee DF, Hurst BL, Wong MH, Glazer RI, Rahman A, Sidwell RW:
Efficacy of N-methanocarbathymidine in treating mice
infected intranasally with the IHD and WR strains of vaccinia
virus.  Antiviral Res 2007, 76(2):124-129.
14. Moyer RW, Rothe CT: The white pock mutants of rabbit pox-
virus. I. Spontaneous host range mutants contain deletions.
Virology 1980, 102(1):119-132.
15. Marquez VE, Hughes SH, Sei S, Agbaria R: The history of N-meth-
anocarbathymidine: the investigation of a conformational
concept leads to the discovery of a potent and selective nucl-
eoside antiviral agent.  Antiviral Res 2006, 71(2-3):268-275.
16. Turner PC, Moyer RW: A PCR-based method for manipulation
of the vaccinia virus genome that eliminates the need for
cloning.  Biotechniques 1992, 13(5):764-771.